BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 22, 2010
View Archived Issues
Archemix Could Get $315M in Baxter Hemophilia Assets Deal
Read More
Inspiration Starts Hemophilia Phase II/III, Collects $50M
Read More
Somaxon Adding $26M; Sales Efforts for Silenor Under Way
Read More
Stock Movers
Read More
White House Honors Top U.S. Scientists, Innovators
Read More
Clinic Roundup
Read More
Other News To Note
Read More
EORTC Roundup
Read More
Bench Press
Read More
Amgen Wins D-Mab OK for Fractures in Cancer Patients
WASHINGTON – The FDA late Thursday approved Amgen Inc.'s denosumab 120 mg as a therapy to prevent skeletal-related events (SRE) in patients with bone metastases from solid tumors. (BioWorld Today)
Read More
BTG Grabs Biocompatibles for $284.5M in All-Share Deal
Read More